Events & Presentations

Archived Events

Date	Title
March 30, 2021	Fourth Quarter and Full Year 2020 Financial Results Conference Call Click Here for Webcast Fourth Quarter and Full Year 2020 Financial Results Conference Call Presentation 6.8 MB
January 11, 2021	J.P. Morgan Healthcare Conference Click here for Webcast J.P. Morgan Healthcare Conference Presentation 7.8 MB
December 3, 2020	Evercore ISI 3rd Annual HealthCONx Conference Click Here for Webcast

Presentations

Fourth Quarter and Full Year 2020 Financial Results Conference Call Presentation

High Lung Levels of Active Triphosphate Predicted with Oral AT-527 in COVID Patients, Atea Science Spotlight presentation at 28th Annual Conference on Retroviruses and Opportunistic Infections (CROI)

J.P. Morgan Healthcare Conference Presentation

A combination of AT-527, a Pan-Genotypic Guanosine Nucleotide Prodrug, and Daclatasvir was Well-Tolerated and Effective in HCV-Infected Subjects

Source

The Digital International Liver Congress™ 2020, the Annual Meeting of the European Association for the Study of the Liver (EASL), August 27, 2020

HCV Viral Kinetic Analysis Predicts Shorter Treatment duration with AT-527, a Purine Nucleotide Prodrug with Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects Regardless of Cirrhosis Status

Source

The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 8-12, 2019

AT-527, a Purine Nucleotide Prodrug, Exhibits Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects with Cirrhosis

Source

The 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, November 9-13, 2018

AT-527, a Pan-Genotypic Purine Nucleotide Prodrug, Exhibits Potent Antiviral Activity in Subjects with Chronic Hepatitis C

Source

The International Liver Congress™ 2018 (ILC 2018), the 53rd Annual Meeting of the European Association for the Study of the Liver (EASL), Paris, France, April 11-15, 2018

A Phase 1a Study of AT-527, a Novel Pan-Genotypic Purine Nucleotide Prodrug Inhibitor of Hepatitis C Virus (HCV)

Source

The 68th Annual Meeting of the American Association for the Study of Liver diseases (AASLD), Washington DC, October 20-24, 2017

AT-337, AT-511 and its Salt Form, AT-527: Novel Potent and Selective Pan-Genotypic Purine Nucleotide Prodrug Inhibitors of HCV Polymerase

Source

The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, November 11-15, 2016

Investor Relations

Events & Presentations

Events & Presentations